A Phase II Study Using Talimogene Laherparepvec as a Single Agent for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 22 Jan 2018 Planned End Date changed from 1 Aug 2021 to 1 Aug 2022.
- 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Aug 2016 Planned primary completion date changed from 1 Jul 2021 to 1 Aug 2021.